Idenix's (IDIX) Renaud Says Will Take 18-24 Months to Resolve Patent Case with Gilead (GILD) -Reuters
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Traders should watch Idenix Pharma (Nasdaq: IDIX) shares as Reuters is reporting the company's CEO Ron Renaud has said he believes it will take about 18-24 months in order to resolve the patent cases with Gilead (Nasdaq: GILD).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quantum Cyber rejects short-seller's offer to halt reports if lawsuit dropped
- Silver Lake In Talks To Buy Workday, Sources Say - Reuters
- Software M&A heats up: Which SaaS stocks could be next for private equity?
Create E-mail Alert Related Categories
Litigation, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
